查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1944262

慢性阻塞性肺病（COPD）治療全球市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

慢性阻塞性肺病(COPD) 治療市場規模預計將從 2025 年的 293.1 億美元成長到 2034 年的 455.5 億美元，2026 年至 2034 年的複合年成長率為 5.02%。

隨著慢性阻塞性肺病（COPD）在全球盛行率持續上升，COPD治療市場預計將迎來顯著成長。 COPD是一種進行性肺部疾病，其特徵是氣流受限，導致呼吸困難和生活品質下降。吸菸、空氣污染和職業暴露等風險因素的增加，推動了對有效COPD治療藥物的需求，包括支氣管擴張劑、皮質類固醇和聯合治療。隨著醫療機構尋求改善患者預後和控制症狀，COPD治療市場預計將進一步擴大。

技術創新在塑造慢性阻塞性肺病（COPD）治療市場的未來方面發揮關鍵作用。吸入器和霧化器等藥物輸送系統的創新正在提高COPD治療的有效性和便利性。此外，包括行動應用程式和遠端監測設備在內的數位健康技術的整合，正在幫助患者更有效地管理病情。隨著製造商持續加大研發投入，預計COPD治療市場將在各種醫療機構中更廣泛地採用創新解決方案。

此外，對病患教育和自我管理的日益重視正在推動慢性阻塞性肺病（COPD）治療市場的成長。隨著患者對自身病情和治療方案的了解不斷加深，他們對有效自我管理所需的資源和支持系統的需求也日益成長。這一趨勢促使醫療服務提供者、製藥公司和患者權益組織合作，共同開發教育項目，主導患者掌控自身健康。隨著市場的不斷發展，技術整合、患者參與和個人化護理將成為成功的關鍵促進因素。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 繪製滲透率和成長前景圖
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

4. 全球慢性阻塞性肺病(COPD) 治療市場（依藥物類別分類）

  • 市場分析、洞察與預測
  • 聯合治療
  • 支氣管擴張劑
  • 皮質類固醇
  • 磷酸二酯酶4型抑制劑
  • 黏液動力學
  • 其他

5. 全球慢性阻塞性肺病(COPD) 治療市場（按類型分類）

  • 市場分析、洞察與預測
  • 慢性支氣管炎
  • 氣腫

6. 全球慢性阻塞性肺病(COPD) 治療市場（依分銷管道分類）

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

7. 全球慢性阻塞性肺病（COPD）治療市場（按地區分類）

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商格局（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Almirall
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • CHIESI Farmaceutici SP A
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKiine Plc
    • Kyowa Hakko Kirin
    • Mylan NV
    • Novartis AG
    • Orion Corporation
    • Sanofi
    • Sunovion Pharmaceuticals Inc.（Sumitomo Dainippon Pharma Co. Ltd）
    • Teva Pharmaceutical Industries Ltd
    • Theravance Biopharma
    • Verona Pharmaceuticals
簡介目錄
Product Code: VMR11218849

The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market size is expected to reach USD 45.55 Billion in 2034 from USD 29.31 Billion (2025) growing at a CAGR of 5.02% during 2026-2034.

The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is poised for significant growth as the prevalence of COPD continues to rise globally. COPD is a progressive lung disease characterized by airflow limitation, leading to breathing difficulties and reduced quality of life. The increasing incidence of risk factors such as smoking, air pollution, and occupational exposures is driving the demand for effective COPD treatments, including bronchodilators, corticosteroids, and combination therapies. As healthcare providers seek to improve patient outcomes and manage symptoms, the market for COPD treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the COPD treatment market. Innovations in drug delivery systems, such as inhalers and nebulizers, are enhancing the efficacy and convenience of COPD therapies. Additionally, the integration of digital health technologies, including mobile applications and remote monitoring devices, is empowering patients to manage their condition more effectively. As manufacturers continue to invest in research and development, the COPD treatment market is likely to see increased adoption of innovative solutions across various healthcare settings.

Moreover, the growing emphasis on patient education and self-management is influencing the COPD treatment market's growth trajectory. As patients become more informed about their condition and treatment options, there is a rising demand for resources and support systems that facilitate effective self-management. This trend is driving collaboration between healthcare providers, pharmaceutical companies, and patient advocacy groups to develop educational initiatives that empower patients to take control of their health. As the market continues to evolve, the integration of technology, patient engagement, and personalized care will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

  • Combination Therapy
  • Bronchodilators
  • Corticosteroids
  • Phosphodiesterase Type 4 Inhibitor
  • Mucokinetics
  • Others

By Type

  • Chronic Bronchitis
  • Emphysema

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici Sp A, F HoffmannLa Roche Ltd, GlaxoSmithKiine plc, Kyowa Hakko Kirin, Mylan NV, Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd, Teva Pharmaceutical Industries Ltd, Theravance Biopharma, Verona Pharmaceuticals

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Combination Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Bronchodilators Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Phosphodiesterase Type 4 Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Mucokinetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Chronic Bronchitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Emphysema Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Drug Class
    • 7.2.2 By Type
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Drug Class
    • 7.3.2 By Type
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Drug Class
    • 7.4.2 By Type
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Drug Class
    • 7.5.2 By Type
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Drug Class
    • 7.6.2 By Type
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Almirall
    • 9.2.2 AstraZeneca
    • 9.2.3 Boehringer Ingelheim International GmbH
    • 9.2.4 CHIESI Farmaceutici S.P A
    • 9.2.5 F. Hoffmann-La Roche Ltd
    • 9.2.6 GlaxoSmithKiine Plc
    • 9.2.7 Kyowa Hakko Kirin
    • 9.2.8 Mylan NV
    • 9.2.9 Novartis AG
    • 9.2.10 Orion Corporation
    • 9.2.11 Sanofi
    • 9.2.12 Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd)
    • 9.2.13 Teva Pharmaceutical Industries Ltd
    • 9.2.14 Theravance Biopharma
    • 9.2.15 Verona Pharmaceuticals